José Miguel Rivera-Caravaca

Aug 6, 2024 | onlinelibrary.wiley.com | José Miguel Rivera-Caravaca |Liverpool John Moores |Liverpool Heart |Freddy Frost

1 INTRODUCTION Since the initial phases of the coronavirus disease 2019 (COVID-19) pandemic, patients positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were identified as having a prothrombotic profile and therefore a higher risk of thrombosis.1, 2 For this reason, different antithrombotic agents, including oral anticoagulation (OAC), emerged as therapeutic options for preventing and treating COVID-19-associated thrombotic disease.3 Other drugs with pleiotropic actions...

Jul 10, 2023 | mdpi.com | José Miguel Rivera-Caravaca |Jeroen Hendriks |José Miguel Martín Martínez

Open AccessEditorialbyJosé Miguel Rivera-Caravaca 1,2,* and Jeroen M.

Jun 12, 2023 | physiciansweekly.com | Tommaso Bucci |Gashirai K Mbizvo |José Miguel Rivera-Caravaca |Josephine Mayer

The risks of cardiovascular events(CVEs) in people with epilepsy(PWE) are not well understood. To establish the short- and long-term burden of CVEs in PWE. Electronic health records from a global federated health research network(TriNetX) were used to establish a cohort of PWE.